Feng Deng

Feng Deng serves as a Grant-funded researcher and doctoral programme supervisor within the Research Programs Unit at the University of Helsinki, specifically embedded in the Physiology, Genetics and Preanalytics group at Helsinki University Hospital (HUS). His academic role centers on clinical pharmacology research with emphasis on drug transporter mechanisms and therapeutic implications.

His research program investigates critical intersections of pharmacology and clinical practice, particularly focusing on drug-drug interactions mediated by efflux transporters (BCRP, MRPs), statin pharmacokinetics, and pharmacogenetic determinants of drug response. Key methodologies involve in vitro transporter assays and clinical pharmacokinetic studies to evaluate how marketed drugs like ticagrelor and PARP inhibitors modulate transporter activity.

Analysis of Deng's recent publication trajectory (2023-2025) reveals consistent investigation into transporter-mediated drug interactions, with emerging emphasis on cardiovascular drug safety (statin-ticagrelor interactions) and repurposing opportunities for oncology drugs. His work bridges molecular pharmacology with clinical outcomes, generating actionable insights for personalized prescribing.

Deng actively supervises doctoral candidates in the Drug Research Programme and secures competitive research funding. His organizational contributions include membership on the 2021 Pertti Neuvonen Symposium committee, demonstrating leadership in clinical pharmacology knowledge dissemination.

He operates within the Physiology, Genetics and Preanalytics team at HUS, which provides integrated laboratory and clinical research infrastructure for investigating drug disposition mechanisms and biomarker discovery in therapeutic contexts.